Comparison of Lipoprotein-Associated Phospholipase A2 and High Sensitive C-Reactive Protein as Determinants of Metabolic Syndrome in Subjects without Coronary Heart Disease: In Search of the Best Predictor

Abstract EN

High sensitivity C-reactive protein (hsCRP) is a marker of metabolic syndrome (MS) and cardiovascular (CV) disease.

Lipoprotein-associated phospholipase A2 (Lp-PLA2) also predicts CV disease.

There are no reports comparing these markers as predictors of MS.

Methods.

Cross-sectional study comparing Lp-PLA2 and hsCRP as predictors of MS in asymptomatic subjects was carried out; 152 subjects without known atherosclerosis participated.

Data were collected on demographics, cardiovascular risk factors, anthropometric and biochemical measurements, and hsCRP and Lp-PLA2 activity levels.

A logistic regression analysis was performed with each biomarker and receiver operating characteristic (ROC) curves were constructed for MS.

Results.

Mean age was 46 ± 11 years, and 38% of the subjects had MS.

Mean Lp-PLA2 activity was 185 ± 48 nmol/mL/min, and mean hsCRP was 2.1 ± 2.2 mg/L.

Subjects with MS had significantly higher levels of Lp-PLA2 ( P = 0.03 ) and hsCRP ( P < 0.0001 ) than those without MS.

ROC curves showed that both markers predicted MS.

Conclusion.

Lp-PLA2 and hsCRP are elevated in subjects with MS.

Both biomarkers were independent and significant predictors for MS, emphasizing the role of inflammation in MS.

Further research is necessary to determine if inflammation predicts a higher risk for CV events in MS subjects.